JPWO2020084115A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020084115A5
JPWO2020084115A5 JP2021523064A JP2021523064A JPWO2020084115A5 JP WO2020084115 A5 JPWO2020084115 A5 JP WO2020084115A5 JP 2021523064 A JP2021523064 A JP 2021523064A JP 2021523064 A JP2021523064 A JP 2021523064A JP WO2020084115 A5 JPWO2020084115 A5 JP WO2020084115A5
Authority
JP
Japan
Prior art keywords
group
alkylene
substituted
substituents
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523064A
Other languages
English (en)
Japanese (ja)
Other versions
JP7629400B2 (ja
JP2022512830A5 (https=
JP2022512830A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/079188 external-priority patent/WO2020084115A1/en
Publication of JP2022512830A publication Critical patent/JP2022512830A/ja
Publication of JPWO2020084115A5 publication Critical patent/JPWO2020084115A5/ja
Publication of JP2022512830A5 publication Critical patent/JP2022512830A5/ja
Application granted granted Critical
Publication of JP7629400B2 publication Critical patent/JP7629400B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523064A 2018-10-25 2019-10-25 エクテナサイジン誘導体を含む薬物抗体複合体 Active JP7629400B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382759.1 2018-10-25
EP18382759 2018-10-25
PCT/EP2019/079188 WO2020084115A1 (en) 2018-10-25 2019-10-25 Antibody drug conjugates comprising ecteinascidin derivatives

Publications (4)

Publication Number Publication Date
JP2022512830A JP2022512830A (ja) 2022-02-07
JPWO2020084115A5 true JPWO2020084115A5 (https=) 2024-03-21
JP2022512830A5 JP2022512830A5 (https=) 2024-03-21
JP7629400B2 JP7629400B2 (ja) 2025-02-13

Family

ID=64426824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523064A Active JP7629400B2 (ja) 2018-10-25 2019-10-25 エクテナサイジン誘導体を含む薬物抗体複合体

Country Status (37)

Country Link
US (1) US20230012681A1 (https=)
EP (1) EP3870234B1 (https=)
JP (1) JP7629400B2 (https=)
KR (1) KR20210086669A (https=)
CN (1) CN113226377B (https=)
AR (1) AR117657A1 (https=)
AU (1) AU2019368687B2 (https=)
BR (1) BR112021007718A2 (https=)
CA (1) CA3117268C (https=)
CL (1) CL2021001039A1 (https=)
CO (1) CO2021006838A2 (https=)
DK (1) DK3870234T3 (https=)
EA (1) EA202191131A1 (https=)
EC (1) ECSP21035414A (https=)
ES (1) ES2939494T3 (https=)
FI (1) FI3870234T3 (https=)
HR (1) HRP20230275T1 (https=)
HU (1) HUE061606T2 (https=)
IL (1) IL282577B2 (https=)
JO (1) JOP20210083B1 (https=)
LT (1) LT3870234T (https=)
MA (1) MA59661B1 (https=)
MD (1) MD3870234T2 (https=)
MX (1) MX2021004746A (https=)
MY (1) MY206221A (https=)
PH (1) PH12021550930A1 (https=)
PL (1) PL3870234T3 (https=)
PT (1) PT3870234T (https=)
RS (1) RS64068B1 (https=)
SA (1) SA521421855B1 (https=)
SG (1) SG11202104154WA (https=)
SI (1) SI3870234T1 (https=)
SM (1) SMT202300076T1 (https=)
TW (1) TWI824043B (https=)
UA (1) UA129803C2 (https=)
WO (1) WO2020084115A1 (https=)
ZA (1) ZA202103478B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231233T1 (hr) * 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
TW202313039A (zh) * 2021-05-19 2023-04-01 西班牙商瑪製藥股份有限公司 Pm14用途與方案
KR102625740B1 (ko) * 2021-07-15 2024-01-17 주식회사 새한비엠 폐수지 재료 및 미네랄 바인더를 이용한 단열차음재의 제조 방법 및 그 단열차음재
CN120417935A (zh) * 2022-10-25 2025-08-01 默沙东有限责任公司 依喜替康衍生的adc接头-载荷及其药物组合物和用途
WO2024155565A2 (en) * 2023-01-17 2024-07-25 Yarrow Therapeutics, Inc. Ecteinascidin derivative antibody drug conjugates
WO2024186263A1 (en) 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives
CN118878690B (zh) * 2023-11-28 2026-01-09 南京大学 一种抗地高辛纳米抗体的制备及其应用
WO2025228595A1 (en) * 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of compound ia in the treatment of cancers including combination therapy with atezolizumab.
TW202547488A (zh) * 2024-04-30 2025-12-16 西班牙商瑪製藥股份有限公司 於癌症的治療中之化合物Ia和拓樸異構酶I抑制劑的組合
WO2025233522A1 (en) * 2024-05-10 2025-11-13 Pharma Mar, S.A. Synthetic process for an ecteinascidin

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
AR054181A1 (es) * 2004-08-26 2007-06-06 Nicholas Piramal India Ltd Prodrogas que contienen enlaces bio-divisibles. composiiciones farmaceuticas
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
EP3539572A1 (en) 2005-08-24 2019-09-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
GB201506405D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
HRP20231233T1 (hr) * 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
KR20230004714A (ko) * 2020-04-21 2023-01-06 파르마 마르, 에스.에이. 약물 항체 접합체

Similar Documents

Publication Publication Date Title
HRP20230275T1 (hr) Antitijelo-lijek konjugati koji sadrže derivate ekteinascidina
US12180552B2 (en) Site-specific conjugation of linker drugs to antibodies and resulting ADCs
US11819553B2 (en) Glypican 3 antibodies and conjugates thereof
CN107921144B (zh) 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物
JP2024521629A (ja) 抗体薬物コンジュゲート、及びその調製方法及びその使用
JPWO2020084115A5 (https=)
BR112020020466A2 (pt) Conjugados de peptídeo de camptotecina
RU2015156499A (ru) Конъюгаты антитела с лекарственным средством
JP2023520930A (ja) 電荷多様性リンカー
CN109912683A (zh) 一种细胞毒素分子、偶联物及其制备方法和应用
KR20140139480A (ko) 항체-약물 접합체 및 관련 화합물, 조성물, 및 방법
CA3016172A1 (en) Derivatives of amanita toxins and their conjugation to a cell binding molecule
PL172824B1 (pl) Nowe koniugaty tioeterowe PL PL PL PL PL
JP6957629B2 (ja) 非線状自壊性リンカーおよびそのコンジュゲート
CA3204418A1 (en) Linker-payloads and conjugates thereof
JPWO2020200880A5 (https=)
JPWO2020252294A5 (https=)
AU2019452577B2 (en) Cell-binding molecule-Tubulysin derivative conjugate and preparation method therefor
JP2018524313A (ja) キネシンスピンドルタンパク質(ksp)阻害剤の抗b7h3抗体との抗体薬物複合体
JPWO2022022508A5 (https=)
KR20250137203A (ko) 항체 약물 접합체
JP2019507126A5 (https=)
JPWO2021214126A5 (https=)
JPWO2021174113A5 (https=)
JPWO2021043951A5 (https=)